Jhanelle E Gray1, Jeffrey R Infante2, Les H Brail3,4, George R Simon5, Jennifer F Cooksey1, Suzanne F Jones2, Daphne L Farrington3, Adeline Yeo6,7, Kimberley A Jackson3, Kay H Chow3, Maciej J Zamek-Gliszczynski3,8, Howard A Burris9. 1. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. 2. Sarah Cannon Research Institute and Tennessee Oncology, 250 25th Avenue North, Suite 200, Nashville, TN, 37203, USA. 3. Eli Lilly and Company, Indianapolis, IN, USA. 4. Infinity Pharmaceuticals, Cambridge, MA, USA. 5. MD Anderson Cancer Center, Houston, TX, USA. 6. DOCS, San Diego, CA, USA. 7. Stat4ward LLC, Pittsburgh, PA, USA. 8. GlaxoSmithKline, Research Triangle Park, North Caroline, USA. 9. Sarah Cannon Research Institute and Tennessee Oncology, 250 25th Avenue North, Suite 200, Nashville, TN, 37203, USA. howard.burris@scresearch.net.
Abstract
PURPOSE: LY2090314 (LY) is a glycogen synthase kinase 3 inhibitor with preclinical efficacy in xenograft models when combined with platinum regimens. A first-in-human phase 1 dose-escalation study evaluated the combination of LY with pemetrexed/carboplatin. PATIENTS AND METHODS: Forty-one patients with advanced solid tumors received single-dose LY monotherapy lead-in and 37 patients received LY (10-120 mg) plus pemetrexed/carboplatin (500 mg/m(2) and 5-6 AUC, respectively) across 8 dose levels every 21 days. Primary objective was maximum tolerated dose (MTD) determination; secondary endpoints included safety, antitumor activity, pharmacokinetics, and beta-catenin pharmacodynamics. RESULTS: MTD of LY with pemetrexed/carboplatin was 40 mg. Eleven dose-limiting toxicities (DLTs) occurred in ten patients. DLTs during LY monotherapy occurred at ≥ 40 mg: grade 2 visual disturbance (n = 1) and grade 3/4 peri-infusional thoracic pain during or shortly post infusion (n = 4; chest, upper abdominal, and back pain). Ranitidine was added after de-escalation to 80 mg LY to minimize peri-infusional thoracic pain. Following LY with pemetrexed/carboplatin therapy, DLTs included grade 3/4 thrombocytopenia (n = 4) and grade 4 neutropenia (n = 1). Best overall response by RECIST included 5 confirmed partial responses (non-small cell lung cancer [n = 3], mesothelioma, and breast cancer) and 19 patients having stable disease. Systemic LY exposure was approximately linear over dose range studied. Transient upregulation of beta-catenin measured in peripheral blood mononuclear cells (PBMCs) occurred at 40 mg LY. CONCLUSIONS: The initial safety profile of LY2090314 was established. MTD LY dose with pemetrexed/carboplatin is 40 mg IV every 3 weeks plus ranitidine. Efficacy of LY plus pemetrexed/carboplatin requires confirmation in randomized trials.
PURPOSE:LY2090314 (LY) is a glycogen synthase kinase 3 inhibitor with preclinical efficacy in xenograft models when combined with platinum regimens. A first-in-human phase 1 dose-escalation study evaluated the combination of LY with pemetrexed/carboplatin. PATIENTS AND METHODS: Forty-one patients with advanced solid tumors received single-dose LY monotherapy lead-in and 37 patients received LY (10-120 mg) plus pemetrexed/carboplatin (500 mg/m(2) and 5-6 AUC, respectively) across 8 dose levels every 21 days. Primary objective was maximum tolerated dose (MTD) determination; secondary endpoints included safety, antitumor activity, pharmacokinetics, and beta-catenin pharmacodynamics. RESULTS: MTD of LY with pemetrexed/carboplatin was 40 mg. Eleven dose-limiting toxicities (DLTs) occurred in ten patients. DLTs during LY monotherapy occurred at ≥ 40 mg: grade 2 visual disturbance (n = 1) and grade 3/4 peri-infusional thoracic pain during or shortly post infusion (n = 4; chest, upper abdominal, and back pain). Ranitidine was added after de-escalation to 80 mg LY to minimize peri-infusional thoracic pain. Following LY with pemetrexed/carboplatin therapy, DLTs included grade 3/4 thrombocytopenia (n = 4) and grade 4 neutropenia (n = 1). Best overall response by RECIST included 5 confirmed partial responses (non-small cell lung cancer [n = 3], mesothelioma, and breast cancer) and 19 patients having stable disease. Systemic LY exposure was approximately linear over dose range studied. Transient upregulation of beta-catenin measured in peripheral blood mononuclear cells (PBMCs) occurred at 40 mg LY. CONCLUSIONS: The initial safety profile of LY2090314 was established. MTD LY dose with pemetrexed/carboplatin is 40 mg IV every 3 weeks plus ranitidine. Efficacy of LY plus pemetrexed/carboplatin requires confirmation in randomized trials.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Anil Kumar; Xu Hou; Chunsik Lee; Yang Li; Arvydas Maminishkis; Zhongshu Tang; Fan Zhang; Harald F Langer; Pachiappan Arjunan; Lijin Dong; Zhijian Wu; Linda Y Zhu; Lianchun Wang; Wang Min; Peter Colosi; Triantafyllos Chavakis; Xuri Li Journal: J Biol Chem Date: 2010-03-15 Impact factor: 5.157
Authors: Patrick W B Derksen; Esther Tjin; Helen P Meijer; Melanie D Klok; Harold D MacGillavry; Marinus H J van Oers; Henk M Lokhorst; Andries C Bloem; Hans Clevers; Roel Nusse; Ronald van der Neut; Marcel Spaargaren; Steven T Pals Journal: Proc Natl Acad Sci U S A Date: 2004-04-05 Impact factor: 11.205
Authors: Robin E Bachelder; Sang-Oh Yoon; Clara Franci; Antonio García de Herreros; Arthur M Mercurio Journal: J Cell Biol Date: 2005-01-03 Impact factor: 10.539
Authors: Florence F Wagner; Lina Benajiba; Arthur J Campbell; Michel Weïwer; Joshua R Sacher; Jennifer P Gale; Linda Ross; Alexandre Puissant; Gabriela Alexe; Amy Conway; Morgan Back; Yana Pikman; Ilene Galinsky; Daniel J DeAngelo; Richard M Stone; Taner Kaya; Xi Shi; Matthew B Robers; Thomas Machleidt; Jennifer Wilkinson; Olivier Hermine; Andrew Kung; Adam J Stein; Damodharan Lakshminarasimhan; Michael T Hemann; Edward Scolnick; Yan-Ling Zhang; Jen Q Pan; Kimberly Stegmaier; Edward B Holson Journal: Sci Transl Med Date: 2018-03-07 Impact factor: 17.956
Authors: Amy Walz; Andrey Ugolkov; Sunandana Chandra; Alan Kozikowski; Benedito A Carneiro; Thomas V O'Halloran; Francis J Giles; Daniel D Billadeau; Andrew P Mazar Journal: Clin Cancer Res Date: 2017-01-04 Impact factor: 12.531
Authors: Alberto M Martelli; Camilla Evangelisti; Francesca Paganelli; Francesca Chiarini; James A McCubrey Journal: Leukemia Date: 2021-04-02 Impact factor: 11.528
Authors: A H M de Vries Schultink; A A Suleiman; J H M Schellens; J H Beijnen; A D R Huitema Journal: Eur J Clin Pharmacol Date: 2016-02-26 Impact factor: 2.953
Authors: Beverly A Teicher; Thomas Silvers; Michael Selby; Rene Delosh; Julie Laudeman; Chad Ogle; Russell Reinhart; Ralph Parchment; Julia Krushkal; Dmitriy Sonkin; Larry Rubinstein; Joel Morris; David Evans Journal: Cancer Med Date: 2017-08-01 Impact factor: 4.452